Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature

被引:12
作者
Arpinelli, Fabio [1 ]
Carone, Mauro [2 ]
Riccardo, Gioacchino [1 ]
Bertolotti, Giorgio [3 ]
机构
[1] GSK Med & Sci Dept, Verona, Italy
[2] IRCCS, Fdn Salvatore Maugeri, Div Pneumol, Cassano Delle Murge, Italy
[3] IRCCS, Fdn Salvatore Maugeri, Psychol Serv, Tradate, Italy
关键词
Asthma; COPD; Asthma quality of life questionnaire; Health-related quality of life; Saint George's respiratory questionnaire;
D O I
10.1186/s40248-016-0040-9
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Asthma and chronic obstructive pulmonary disease (COPD) are frequent in the general population. These diseases can worsen the quality of life of people suffering from them, limiting their daily activities and disrupting their sleep at night. Some questionnaires to measure the impact of the diseases on the daily life of patients are available. The measurements of subjective outcomes have become a part of clinical practice, and are used very frequently in clinical trials. Our aim was to describe how data on HRQoL in asthma and COPD are reported in papers published in the medical literature. Methods: We identified papers on the recent respiratory drugs (chemical, not biological), that reported the HRQoL measurement and that were published from 2009 to April 2014. We planned to describe data about HRQoL, and we had no intention of comparing the degree of efficacy of drugs. Results: The most used questionnaires are the Asthma Quality of Life Questionnaire (AQLQ) and the Saint George's Respiratory Questionnaire (SGRQ). These tools, administered at the baseline and at the end of the study (and interim evaluations in the longer studies) allowed for the identification of improvements as perceived by the patient after the treatment, even if in some cases these improvements were limited and not clinically relevant. Subjective measurements have always been placed among the secondary endpoints and the number of patients (estimated for the main endpoint) has often statistically overestimated the result. In addition, it is clear that subjective data is normally reported, but rarely commented on. Conclusions: There are some methodology aspects that should be discussed in more depth, for example the necessity to express variations in the subjective perception, not as p-value but as effect-size.
引用
收藏
页数:7
相关论文
共 41 条
[1]   Characterisation of COPD heterogeneity in the ECLIPSE cohort [J].
Agusti, Alvar ;
Calverley, Peter M. A. ;
Celli, Bartolome ;
Coxson, Harvey O. ;
Edwards, Lisa D. ;
Lomas, David A. ;
MacNee, William ;
Miller, Bruce E. ;
Rennard, Steve ;
Silverman, Edwin K. ;
Tal-Singer, Ruth ;
Wouters, Emiel ;
Yates, Julie C. ;
Vestbo, Jorgen .
RESPIRATORY RESEARCH, 2010, 11
[2]   A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients [J].
Bateman, E. D. ;
Tashkin, D. ;
Siafakas, N. ;
Dahl, R. ;
Towse, L. ;
Massey, D. ;
Pavia, D. ;
Zhong, N. S. .
RESPIRATORY MEDICINE, 2010, 104 (10) :1460-1472
[3]   Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma [J].
Bateman, Eric D. ;
Kornmann, Oliver ;
Schmidt, Peter ;
Pivovarova, Anna ;
Engel, Michael ;
Fabbri, Leonardo M. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (02) :315-322
[4]   Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial [J].
Bodzenta-Lukaszyk, Anna ;
van Noord, Jan ;
Schroeder-Babo, Winfried ;
McAulay, Kirsten ;
McIver, Tammy .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (05) :579-588
[5]   Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler [J].
Bodzenta-Lukaszyk, Anna ;
Pulka, Grazyna ;
Dymek, Andrzej ;
Bumbacea, Dragos ;
McIver, Tammy ;
Schwab, Birgit ;
Mansikka, Heikki .
RESPIRATORY MEDICINE, 2011, 105 (05) :674-682
[6]  
Bodzenta-Lukaszyk Buhl R, 2012, J ASTHMA, V49, P1060
[7]   Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD [J].
Buhl, R. ;
Dunn, L. J. ;
Disdier, C. ;
Lassen, C. ;
Amos, C. ;
Henley, M. ;
Kramer, B. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (04) :797-803
[8]   Beclomethasone/formoterol in the management of COPD: A randomised controlled trial [J].
Calverley, P. M. A. ;
Kuna, P. ;
Monso, E. ;
Costantini, M. ;
Petruzzelli, S. ;
Sergio, F. ;
Varoli, G. ;
Papi, A. ;
Brusasco, V. .
RESPIRATORY MEDICINE, 2010, 104 (12) :1858-1868
[9]   Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD A Randomized, Controlled Study [J].
Celli, Bartolome ;
Crater, Glenn ;
Kilbride, Sally ;
Mehta, Rashmi ;
Tabberer, Maggie ;
Kalberg, Chris J. ;
Church, Alison .
CHEST, 2014, 145 (05) :981-991
[10]   Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial [J].
D'Urzo, Anthony ;
Ferguson, Gary T. ;
van Noord, Jan A. ;
Hirata, Kazuto ;
Martin, Carmen ;
Horton, Rachael ;
Lu, Yimeng ;
Banerji, Donald ;
Overend, Tim .
RESPIRATORY RESEARCH, 2011, 12